Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

This study is a randomized, open-label, multi-cohort, multicenter clinical trial, aimed at evaluating the efficacy and safety of Fluzoparib monotherapy, Fluzoparib in combination with Bevacizumab, and standard chemotherapy (Paclitaxel plus Carboplatin) as neoadjuvant treatments in newly diagnosed, germline BRCA1/2-mutated epithelial ovarian cancer patients (FIGO stage III/IV). The study also aims to assess the efficacy and safety of Fluzoparib as maintenance therapy following surgery and chemotherapy. The primary endpoint of the study is the objective response rate (ORR) for neoadjuvant thera

Trial Details

NCT ID
NCT06735326
Phase
PHASE2
Sponsor
Qilu Hospital of Shandong University
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Fluzoparib
  • Bevacizumab
  • Paclitaxel
  • Carboplatin
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • The subject voluntarily agrees to participate and signs the informed consent form.
  • Age ≥18 years (calculated as of the date of signing the informed consent).
  • Pathologically diagnosed with newly diagnosed, FIGO stage III-IV high-grade (or moderate/low-grade) serous ovarian cancer, fallopian tube cancer, o…
  • The subject has at least one measurable lesion that can be assessed by CT or MRI (RECIST v1.1).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →